Developing precision medicines for kidney diseases
Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.
Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. These dynamics converge to create very attractive opportunities for Chinook to develop a portfolio of precision medicines for kidney diseases.
At Chinook, we are focused on developing therapeutics for rare, severe kidney disorders with defined and rapid clinical development pathways. Our lead program, atrasentan, is a late-stage clinical program for the treatment of primary glomerular kidney diseases. In addition, we have a lead preclinical program positioned for a 1H 2021 IND in an ultra-orphan kidney disease indication, as well as multiple research programs for polycystic kidney disease. We are also applying our proprietary discovery platform, which leverages single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with novel mechanisms of action against key kidney disease pathways.
Chinook is anchored by our highly experienced drug discovery and development teams.
Chinook plans to initiate a Phase 3 clinical trial of atrasentan in the second half of 2020 for biomarker-selected patients with a rare primary glomerular kidney disease at high risk for progressive kidney function loss.
Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases
Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases